KALA
Price
$3.15
Change
-$0.40 (-11.30%)
Updated
Jun 23, 04:58 PM (EDT)
Capitalization
58M
Intraday BUY SELL Signals
PALI
Price
$1.93
Change
+$0.09 (+4.89%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
337.13M
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KALA vs PALI

KALA vs PALI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KALA vs. PALI commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KALA is a Hold and PALI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (KALA: $3.54 vs. PALI: $1.84)
Brand notoriety: KALA and PALI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KALA: 118% vs. PALI: 63%
Market capitalization -- KALA: $65.81M vs. PALI: $319.75M
KALA [@Biotechnology] is valued at $65.81M. PALI’s [@Biotechnology] market capitalization is $319.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KALA’s FA Score shows that 0 FA rating(s) are green whilePALI’s FA Score has 0 green FA rating(s).

  • KALA’s FA Score: 0 green, 5 red.
  • PALI’s FA Score: 0 green, 5 red.
According to our system of comparison, PALI is a better buy in the long-term than KALA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KALA’s TA Score shows that 4 TA indicator(s) are bullish while PALI’s TA Score has 4 bullish TA indicator(s).

  • KALA’s TA Score: 4 bullish, 4 bearish.
  • PALI’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PALI is a better buy in the short-term than KALA.

Price Growth

KALA (@Biotechnology) experienced а +34.09% price change this week, while PALI (@Biotechnology) price change was +8.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

PALI is expected to report earnings on Aug 25, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PALI($337M) has a higher market cap than KALA($58M). PALI YTD gains are higher at: -21.702 vs. KALA (-87.264). KALA has higher annual earnings (EBITDA): -17.22M vs. PALI (-24.14M). PALI has more cash in the bank: 133M vs. KALA (8.76M). KALA has less debt than PALI: KALA (0) vs PALI (211K). KALA (0) and PALI (0) have equivalent revenues.
KALAPALIKALA / PALI
Capitalization58M337M17%
EBITDA-17.22M-24.14M71%
Gain YTD-87.264-21.702402%
P/E RatioN/A15.33-
Revenue00-
Total Cash8.76M133M7%
Total Debt0211K-
FUNDAMENTALS RATINGS
KALA vs PALI: Fundamental Ratings
KALA
PALI
OUTLOOK RATING
1..100
3568
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6540
P/E GROWTH RATING
1..100
9753
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALA's Valuation (68) in the Pharmaceuticals Major industry is in the same range as PALI (70) in the null industry. This means that KALA’s stock grew similarly to PALI’s over the last 12 months.

KALA's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PALI (100) in the null industry. This means that KALA’s stock grew similarly to PALI’s over the last 12 months.

PALI's SMR Rating (98) in the null industry is in the same range as KALA (100) in the Pharmaceuticals Major industry. This means that PALI’s stock grew similarly to KALA’s over the last 12 months.

PALI's Price Growth Rating (40) in the null industry is in the same range as KALA (65) in the Pharmaceuticals Major industry. This means that PALI’s stock grew similarly to KALA’s over the last 12 months.

PALI's P/E Growth Rating (53) in the null industry is somewhat better than the same rating for KALA (97) in the Pharmaceuticals Major industry. This means that PALI’s stock grew somewhat faster than KALA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KALAPALI
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 20 days ago
84%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KALA
Daily Signal:
Gain/Loss:
PALI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIVDX21.230.06
+0.28%
American Funds International Vntg R-2
DISVX33.980.02
+0.06%
DFA International Small Cap Value I
OISGX17.89N/A
N/A
Optimum Small-Mid Cap Growth Instl
TFCCX21.95N/A
N/A
Touchstone Large Cap C
MADFX38.10N/A
N/A
Matrix Advisors Dividend

KALA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALA has been closely correlated with MLTX. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if KALA jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALA
1D Price
Change %
KALA100%
-1.94%
MLTX - KALA
82%
Closely correlated
+15.33%
AUPH - KALA
45%
Loosely correlated
+6.50%
LRMR - KALA
38%
Loosely correlated
+0.55%
PALI - KALA
31%
Poorly correlated
-1.60%
SYRE - KALA
29%
Poorly correlated
+13.54%
More

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-1.60%
RNAC - PALI
81%
Closely correlated
+3.32%
AGEN - PALI
81%
Closely correlated
+1.33%
NCNA - PALI
81%
Closely correlated
-4.45%
TAOX - PALI
81%
Closely correlated
-1.09%
NRXP - PALI
74%
Closely correlated
-1.76%
More